Affiliations: Department of Pathology, G. Gennimatas Athens General Hospital, Bldg. #1, 1st Floor 154, Messogion Avenue GR-115 27 Athens, Greece. Tel.: +11 30 210 778 4302; Fax: +11 30 201 778 4302; E-mail: gkonto@med.uoa.gr | [x] The University of Medicine and Pharmacy Iuliu Hatieganu, Cluj, Napoca, Romania | [y] National Cancer Research Center, Istituto Tumori G Paolo II, IRCCS, Bari, Italy
Abstract: Endocrine tumors were considered relatively infrequent neoplasms. However, during the last decades, their frequency gradually increased. The use of imaging techniques, guided FNA biopsy, an endoscope camera in the investigation of endocrine lesions, permits early diagnosis. At the histological level, new applications such as non-biotin containing immunohistochemical detection systems, tyramide amplification method, in situ hybridization, FISH, CGH, and other molecular techniques have provided better knowledge on the protein and molecular background. The investigation of somatostatin and dopamine receptors assists targeted therapy of endocrine tumors. Novel treatment modalities have emerged for the management of pituitary and gastroenteropancreatic tumors respectively. Despite this progress, in some instances, the morphological diagnosis remains questionable. Similarities among normal elements, hyperplastic conditions and benign or malignant lesions can make separation difficult. The “gray zones” representing the overlapping in the sequence of normal parenchyma/ hyperplasia/ adenoma/ carcinoma signify a difficult and controversial diagnostic task, which merits special attention. Furthermore, in most endocrine tumors, the diagnosis of carcinoma is justified only in the presence of local or distant metastases. More precise guidelines are needed, by improving the currently available criteria, to minimize the “gray zones”, leading to a more accurate separation of such endocrine lesions.
